Aprea Therapeutics, Inc. (APRE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
535 Boylston St.
Boston, MA 02116
United States of America (the)
Phone
617-463-9385
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
October 03, 2019
| Name | Title | Pay | Year Born |
| Oren Gilad | Co-Founder, Chief Executive Officer, President and Director | 598,886 | 1968 |
| John Hamill | Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Secretary | 461,444 | 1964 |
| Lars Abrahmsen | Senior Vice President & Chief Scientific Officer | 0 | 1957 |
| Michel Afargan | Head of Pharmacology Development | 0 | N/A |
| Eugene Kennedy | Chief Medical Advisor | 0 | 1969 |
| Brian Wiley | Senior Vice President of Corporate Development & Strategy | 0 | 1968 |
| Zeev Weiss | Chief Business Advisor | 0 | 1962 |
| Andrea Epstein | Controller | 0 | N/A |
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.